COMMUNIQUÉS West-GlobeNewswire

Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe
27/10/2025
Saint-Herblain (France), le 27 octobre 202 5 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des [...]
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
27/10/2025
Saint- Herblain (France), October 27 , 202 5 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with [...]
Hapbee Appoints New Leaders to Accelerate Women’s Wellness Through Frequency Healing Technology
27/10/2025
Expanding focus into FemTech positions Hapbee to scale across a USD 177 billion market by uniting neuroscience, sleep optimization, and women-led innovation VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE [...]
Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform
27/10/2025
Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies JACKSON CENTER, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) [...]
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
27/10/2025
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for the many patients [...]
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
27/10/2025
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
27/10/2025
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that [...]
Labviva Announces Smart Suppliers of the Future Program, Accelerates the Amazonification of Life Sciences Procurement
27/10/2025
Company increases European customer-supplier relationships by 200% this year BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Labviva , the leading AI-powered procurement platform for life sciences, today announced the launch [...]
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
27/10/2025
Initial Clinical Data Expected in the First Half of 2026 SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes [...]
Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026
27/10/2025
Pharmacy Times Annual Survey Recognizes FOCUSfactor as the Leading Pharmacist-Recommended Brand in the Memory-Support Category WESTBROOK, Maine, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) , a [...]
Medera Announces First Patient Dosed in Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial Evaluating SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
27/10/2025
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that [...]
Apyx Medical Corporation to Participate in Upcoming November Investor Conferences
27/10/2025
CLEARWATER, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold [...]
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
27/10/2025
Brekiya ® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE [...]
OXB to participate in upcoming investor conferences and events
27/10/2025
OXB to participate in upcoming investor conferences and events Oxford, UK – 27 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that members of its senior [...]
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
27/10/2025
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership deals Her more than 30 years of [...]
Inspire Medical Systems, Inc. to Present at the 2025 UBS Global Healthcare Conference
27/10/2025
MINNEAPOLIS, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Simbryo Technologies Introduces Personalized Assay to Help IVF Patients Avoid Repeated Failed Transfers
27/10/2025
New diagnostic addresses critical gap in IVF care—measuring whether the uterus is ready to support an embryo Study shows test accurately identifies patients at risk for failed transfers and those with healthy [...]
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
27/10/2025
BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients [...]
Creative Medical Technology Holdings Issues Letter to Shareholders
27/10/2025
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026 PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, [...]

Pages